NSE · VAISHALI · Pharmaceuticals
Vaishali Pharma Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹27 Cr with net profit ₹0 Cr — a 1% net margin, versus 5.27% the period before.
Shareholding
As of 2026-07-31
- Promoter30.54%
- Public69.46%
26,697 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.76× from low to high.
Risk flags
Derived from disclosed data
- Promoter holding fell 1.06 percentage points to 30.54% in the latest disclosure.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #71 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,33,620 Cr | 38.1 | 5.19 | 13.74% | 19.72% |
| Cipla Ltd. | ₹1,12,194 Cr | 25.47 | 3.26 | 11.27% | 14% |
| Zydus Lifesciences Ltd. | ₹1,11,123 Cr | 19.69 | 4.1 | 18.59% | 18.86% |
| Dr Reddys Laboratories Ltd. | ₹1,06,328 Cr | 16.87 | 2.81 | 11.07% | 12.49% |
| Lupin Limited | ₹1,04,830 Cr | 28.2 | 4.67 | 23.76% | 19.4% |
| Mankind Pharma Limited | ₹98,270 Cr | 50.22 | 6.03 | 11.74% | 13.4% |
| Laurus Labs Limited | ₹96,265 Cr | 60.26 | 18.16 | 16.77% | 15.04% |
| Aurobindo Pharma Ltd. | ₹85,509 Cr | 19.32 | 2.26 | 9.25% | 10.5% |
| Biocon Ltd. | ₹67,843 Cr | 40.43 | 1.99 | 1.14% | 2.3% |
| Alkem Laboratories Ltd. | ₹63,322 Cr | 26.94 | 4.58 | 16.66% | 15.65% |
| Vaishali Pharma Limited(this company) | ₹93 Cr | — | 1.35 | 6.03% | 3.86% |
AI analysis
AI-generated · google/gemini-2.5-flashVaishali Pharma Limited has a market capitalization of Rs 102 Cr. The company reported revenue of Rs 102.23 Cr and a profit margin of 386.1%. Its 52-week high is Rs 13.59 and its 52-week low is Rs 4.75. The stock's price-to-earnings (PE) ratio is 24.44, and its debt-to-equity ratio is 0.24.
Positives
- +The company's debt-to-equity ratio is low at 0.24.
- +The profit margin is high at 386.1% for the fiscal year ending March 2025.
- +There is no promoter shareholding pledged (0%).
Negatives
- −Promoter holding has decreased from 56.37% in October 2019 to 30.54% in July 2026.
- −The company's stock is currently under ESM Stage 1 surveillance.
- −No quarterly results have been disclosed since March 2026.
Financial performance
For the fiscal year ending March 2025, Vaishali Pharma Limited reported an annual revenue of Rs 102.23 Cr and a net profit of Rs 0.8174 Cr. Quarterly results show revenue for March 2026 at Rs 26.93 Cr with a net profit of Rs 0.41 Cr. This follows a revenue of Rs 24.65 Cr and net profit of Rs 1.32 Cr in December 2025.
Profitability & returns
The company has a return on equity (ROE) of 6.03% and a return on capital employed (ROCE) of 8.35%. Vaishali Pharma Limited's profit margin stands at 386.1%. The earnings per share (EPS) for the fiscal year ending March 2025 was Rs 0.06.
Balance sheet
Vaishali Pharma Limited's book value is Rs 5.3 per share. The company has a debt-to-equity ratio of 0.24, indicating a low level of debt relative to equity. The company does not currently pay a dividend, with a dividend yield of 0%.
Ownership & pledges
Public shareholding stands at 69.45%. There is no pledged promoter shareholding, with promoter pledge at 0%. The number of shareholders is 26,697.
Regulatory & surveillance
Vaishali Pharma Limited is currently under ESM Stage 1 surveillance, which includes enhanced monitoring mechanisms by the exchange. This indicates specific regulatory scrutiny for the company's stock.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Jul 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.